Chacruna Institute is a registered California 501(c)(3) non-profit. We are a volunteer-led organization run by a team of experts and enthusiasts who give their time freely to bring education and cultural understanding about psychedelic plant medicines to a wider audience. We promote a bridge between the ceremonial use of sacred plants and psychedelic science and envisage a world where plant medicines and other psychedelics are preserved, protected, and valued as part of our cultural identity and integrated into our social, legal and health care systems. Help us to achieve our mission! Please consider becoming a monthly donor so that your impact spans the entire year. Support of any frequency or amount helps the cause.
To make a donation click the button below:
To register for monthly recurrent donations fill the form below:
Please support Chacruna’s work by donating to us. We are an independent organization and we offer free education and advocacy for psychedelic plant medicines. We are a team of dedicated volunteers!
Can you help Chacruna advance cultural understanding around these substances?
Asians and Psychedelics: Transcending the Model MinorityA Conversation With Serena D. Wu, Grace Cepe, and Frances FuWednesday, February 24th, 12-2pm PST
REGISTER FOR THIS EVENT HERE
Psychedelics can be important tools to help transcend the model minority stereotype and bring healing…
Photo, from left to right: Ram Dass, Alfred Matthew Hubbard, Aldous Huxley, Albert Hofmann, Ralph Metzner, Sasha Shulgin, Amanda Feilding, and Maria Sabina.
Chacruna Press Release
Chacruna.net is proud to announce the release of the Statement on Open Science and Open Praxis with Psilocybin, MDMA, and Similar Substances, to which we are a signatory.
Robert Jesse, psychedelic researcher, led the development of the statement, which reflects the history, commitment, and hopes of leaders and organizations in the field of psychedelic research and therapy.
The statement is intended to promote key principles in the research and development of psychedelic medicines, including intellectual and scientific integrity, service, open science and open practices, and non-interference. This document was developed in response to concerns that, as psilocybin and MDMA progress through clinical trials showing promise as medicines, commercial enterprises will form in ways that incentivize them to not share materials or knowledge, to prioritize profits, or to act competitively against others.
For the past century, the field of psychedelics has been marked by cooperation over competition, including the open sharing of knowledge, methods and best practices, and materials. With commercial enterprises taking an interest in psychedelics, journalists, stakeholders, and the general public may need to ask critical questions: Will the new businesses move away from this heritage? Will they seek to interfere with or compete with each other? Do they use exclusive contracts and partnerships to restrict collaboration, sharing of information, or access to materials? Will they assert patent rights? Will they seek regulatory approvals that are tailored to serve the applicant’s financial interests while effectively locking others out? Will they follow the tradition of modest, cost-plus pricing? Or will they employ value-based pricing, charging what the market will bear after potential “competition” has been minimized?
The statement had been signed by numerous scholars, researchers, and practitioners; psychedelic research and service organizations; and philanthropists and foundations. Journalists seeking more information or professionals interested in adding their signature to the statement may write to Bob Jesse: [email protected]
STATEMENT ON OPEN SCIENCE AND OPEN PRAXIS WITH PSILOCYBIN, MDMA, AND SIMILAR SUBSTANCES
Preamble: The undersigned individuals and organizations work to advance the understanding and beneficial uses of substances called (among many names) psychedelics, hallucinogens, or entheogens. Our fields include medicine and traditional healing, medicinal chemistry and ethnopharmacology, psychopharmacology, neuroscience, psychology, counseling, religion, public health, and public policy.
From generations of practitioners and researchers before us, we have received knowledge about these substances, their risks, and ways to use them constructively. In turn, we accept the call to use that knowledge for the common good and to share freely whatever related knowledge we may discover or develop.
Therefore, in this work, we commit to the following principles. If we engage with consultants, contractors, or suppliers, we will do so in ways that uphold these principles.
1. Intellectual and scientific integrity. We affirm that we report the truth as we find it, not as we or others might prefer it to be found. We will present disappointing or adverse results as well as affirming or encouraging ones. We will properly attribute the contributions of others.
2. In service. While we may need to be paid for our labor, we are called to this work in the spirit of service. We will place the common good above private gain, and we will work for the welfare of the individuals and communities served. We will strive to make our expertise and services available to all who may benefit from them, even those whose means are limited.
3. Open science and open praxis. We will not withhold, nor will we require others to withhold, materials or knowledge (experiences, observations, discoveries, methods, best practices, or the like) for commercial advantage. This does not preclude the appropriate management of raw data or the exercise of data exclusivity rights, but we will make those decisions for the common good rather than for private gain. Nor does this preclude reasonable and ordinary charges for our books, other media, software, materials, or professional services.
4. Non-interference. We will strive to place our discoveries into the public domain, for the benefit of all. If we have patents or patents pending, we will license that intellectual property, for no more than reasonable and ordinary administrative costs, to anyone who will use it for the common good and in alignment with these principles.
Signatories may refine or expand their commitments, broadly in keeping with these principles, via further public statements. This document is an evolving work, with signatures being added. They are provisional pending a final release.
Clerk: Robert Jesse. Please email [email protected] if you’d like yourself or your organization to be included.
Scientists, scholars, and practitioners:
Signatories
Affiliations listed for identification only
Ram Dass
Richard Alpert, PhD
Ralph Metzner, PhD
Green Earth Foundation
James Fadiman, PhD
Ann Shulgin
Alexander Shulgin Research Institute
George Greer, MD
Heffer Research Institute
Dennis McKenna, PhD
Heffter Research Institute
Charles S. Grob, MD
UCLA School of Medicine
Harriet de Wit, PhD
University of Chicago
Thomas B Roberts, PhD
Northern Illinois University
Frederick S. Barret, PhD
University of Chicago
Mary P. Cosimano, MSW
Johns Hopkins University School of Medicine
Alan K. Davis, PhD
Johns Hopkins University School of Medicine
Albert Garcia-Romeu, PhD
Johns Hopkins University School of Medicine
Roland R. Griffiths, PhD
Johns Hopkins University School of Medicine
Darrick G. May, PhD
Johns Hopkins University School of Medicine
Brian D. Richards, PsyD
Johns Hopkins University School of Medicine
William A. Richards, PhD
Johns Hopkins University School of Medicine
Janis Phelps, PhD
California Institue of Integral Studies
Kathleen Harrison
Botanical Dimensions
Torsten Passie, MD, MA (phil.)
Hannover Medical School
Katherine A. MacLean, PhD
Michael P. Bogenschultz, MD
New York University
Anthony P. Bossis, PhD
New York University
Jeffrey R. Guss, MD
New York University
Mark A.R. Kleiman, PhD
New York University
Stephen Ross, MD
New York University
Robin Carhart-Harris, PhD
Imperial College London
Mendel Kaelen, PhD
Imperial College London & Wavepaths
Taylor Lyons, PhD (cand.)
Imperial College London
Jonny Martel, MRCP
Imperial College London
Roberta Murphy, MD
Imperial College London
Leor Roseman, PhD
Imperial College London
Ben Sessa, MD
Imperial College London
Christopher Timmermann, PhD (cand)
Imperial College London
Rosalind Watts, DClinPsy
Imperial College London
David Luke, PhD
University of Greenwich
Rita Kočárová, PhD. (cand.)
National Institute of Mental Health, Czech Republic
Tomáš Páleníček, MD, PhD
National Institute of Mental Health, Czech Republic
Filip Tylš, MD, PhD
National Institute of Mental Health, Czech Republic
Miroslav Horák, PhD
Mendel University, Cech Republic
Peter S. Hendricks, PhD
University of Alabama at Birmingham
Brian T. Anderson, MD, MSc
UCSF - University of California, San Francisco
Christopher S. Stauffer, MD
UCSF - University of California, San Francisco
Emily Williams
UCSF - University of California, San Francisco
Alexander B. Belser, PhD (cand.)
Yale University
Benjamin Kelmendi, MD
Yale School of Medicine
Jordan Sloshower, MD MSc
Yale School of Medicine
Rick Doblin, PhD
MAPS
Amy Emerson
MAPS Public Benefit Corp.
Allison Feduccia, PhD
MAPS Public Benefit Corp.
Lisa Jerome, PhD
MAPS Public Benefit Corp.
Ann Mithoefer, BSN
MAPS Public Benefit Corp.
Michael Mithoefer, MD
MAPS Public Benefit Corp.
Berra Yazar-Klosinski, PhD
MAPS
Charles L. Raison, MD
Usona Institue & Med. U. of S. Carolina
Gabor Maté, MD
Simon Fraser University
Adele Getty
Limina Foundation
Jason C. Slot, PhD
Ohio State University
Amanda Feilding
The Beckley Foundation
Matthias E. Liechti, MD, MAS
University Hospital Basel
José Carlos Bouso, PhD
ICEERS, Barcelona
Dráulio Araújo, PhD
Federal University of Rio Grande do Norte, Brazil
Beatriz Labate, PhD
CIIS/CIESAS
Geoff Bathje, PhD
Adler Univeristy, Chicago
Alan Cohn, MD
ECfES.org
James J. Franzo-Eclipse
ECfES.org
Vip B. Short, DC
ECfES.org
Sophia Korb, PhD
Martin Williams, PhD
PRISM, Australia
Gabrielle Agin-Liebes, PhD (cand.)
Palo Alto University
Eric Osborne, MA Ed.
MycoMeditations LLC and PLEDG Inc.
Sunil Kumar Aggarwal, MD, PhD, FAAPMR
University of Washington
Angela Beers, PsyD
shadowmedicine.com
Eleonora Molnar, MA
Women’s Visionary Congress, Canada
Paul Abramson, MD
My Doctor Medical Group & UCSF
Leia Friedman, MS
The Psychedologist
Daniel McQueen, MA
Medicinal Mindfulness
Riccardo Vitale, PhD
UMIYAC, Cartagena, Columbia
Iker Puente, PhD
Barcelona
Rafael Lancelotta
University of Wyoming
Julie Holland, MD
Matthew Brown, DO, MBA
Psych Arts
Sonja Styk, Dr.Med.
Swiss Medical Society for Psycholytic Therapy
Juraj Styk, Dr.Med.
Swiss Medical Society for Psycholytic Therapy
Kevin Franciotti
The New School, New York
Kyle Buller
Psychedelics Today
Meghan Kennedy, LCSW
SuiteEthos, Chicago
Henrik Jungaberle, Dr.sc.hum.
MIND Foundation
Kelan Thomas, PharmD, MS
Touro University California & UCSF
Andrew Penn, MS, NP
UCSF & Kaiser Permanente
Mary McDermott, MFT
Erika Masak-Goldman, LMFT
EMG Clinical Group
Elena Felder, MFT
Efrem Nulman, PhD
Wellness Enterprise
Raymond C. Turpin, PsyD
(Smoky Mountain Psychological Services, PLLC)
Jessica L. Nielson, PhD
(University of Minnesota Medical School)
Heather L. Walker, PhD
Luís Fernando Tófoli
(University of Campinas, Brazil)
Sidarta Ribeiro, PhD
(Federal Univ. of Rio Grande do Norte Natal, Brazil)
K. Casey Alexander Paleos, MD
(New York, NY)
Ray Worthy, PhD, MD
(New Orleans, LA)
Research and service organizations:
Signatories
Multidisciplinary Association for Psychedelic Studies
MAPS
Heffter Research Institute
The Beckley Foundation
Erowid Center
Usona Institute
see usonainstitute.org/openscience
Botanical Dimensions
California Institute of Integral Studies
CIIS
Wavepaths, Ltd.
Chacruna.net
Eugene Center for Ethnobotanical Studies
ECfES.org
Psychedelic Research In Science & Medicine
prism.org.au
Union of Indigenous Yage Medics of the Colombian Amazon
UMIYAC
Khanyisa Healing Gardens NPC, South Africa
International Center for Ethnobotanical Education Research & Service
ICEERS
OPEN Foundation
www.stichtingopen.nl
Medicinal Mindfulness, LLC
Heroic Hearts Project
Earth Medicine Institute
Psychedelics Today
MIND European Foundation for Psychedelic Science
Psychedelic societies and integration circles
Signatories
Label 2
Psychedelic Safety, Support, and Integration, Chicago
Chicago Psychedelic Community
The Psychedelic Society, UK
Portland Psychedelic Society
The Psychedelic Society Germany
Australian Psychedelic Society
Art of Waking Up
Los Angeles
AsiaTripper
Taiwan, HongKong, etc.
Czech Psychedelic Society
czeps.org/en
Supporters, Organizers, publishers, conferences
Signatories
Label 2
Psymposia
Beyond Psychedelics
Czech Republic
Psychedelics and the Future of Psychiatry, Chicago
Melissa Warner
PRISM & Australian Psychedelic Society
Mike Margolies
Joost J. Breeksema, MA
OPEN Foundation, Netherlands
Eric N. Codner, DC
Columbus Physical Medicine Center
Jake Tracy
Michigan State University
Vincent Zeolla, PT, DPT
4D Health & Performance Center)
4D Health & Performance Center
Norwalk, CT
www.drugscience.de
Philanthropists and philanthropic foundations:
Signatories
Robert J. Barnhart
CSP Fund
Betsy Gordon
Bill Linton
Carey and Claudia Turnbull
Riverstyx Foundation
Dr. Bronner’s
George Sarlo Foundation
Evolve.Foundation
Source Research Foundation
The most current version of this statement can be found at csp.org/open.
Please support Chacruna's work by donating to us. We are an independent organization and we offer free education and advocacy for psychedelic plant medicines. We are a team of dedicated volunteers!
Can you help Chacruna advance cultural understanding around these substances?
Asians and Psychedelics: Transcending the Model MinorityA Conversation With Serena D. Wu, Grace Cepe, and Frances FuWednesday, February 24th, 12-2pm PST
REGISTER FOR THIS EVENT HERE
Psychedelics can be important tools to help transcend the model minority stereotype and bring healing...